Tags

Type your tag names separated by a space and hit enter

A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
J Ocul Pharmacol Ther. 2009 Oct; 25(5):447-51.JO

Abstract

INTRODUCTION AND PURPOSE

Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension (OHT). The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure (IOP) after 8 weeks of treatment in patients with primary open angle glaucoma (POAG) or OHT.

METHODS

In this randomized, open-label trial, 44 patients with POAG or OHT were allocated to receive either bimatoprost (1 drop QD) or latanoprost/timolol (1 drop QD). Primary outcome was the mean diurnal IOP measurement at the 8th week, calculated as the mean IOP measurements taken at 8:00 am, 10:00 am, and 12:00 pm Secondary outcomes included the baseline change in IOP measured 3 times a day, after the water-drinking test (performed after the last IOP measurement), and the assessment of side effects of each therapy.

RESULTS

The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8. Also, the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns). During the water-drinking test, there was no significant difference in IOP increase (absolute and percentage) between groups; however, there was a significant decrease in mean heart rate in the latanoprost/timolol group. Finally, no significant changes in blood pressure and lung spirometry were observed in either groups.

CONCLUSIONS

The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT. Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.

Authors+Show Affiliations

Glaucoma Service, Department of Ophthalmology, University of São Paulo School of Medicine, São Paulo, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19860553

Citation

Facio, Antônio Carlos, et al. "A Comparison of Bimatoprost 0.03% Versus the Fixed-combination of Latanoprost 0.005% and Timolol 0.5% in Adult Patients With Elevated Intraocular Pressure: an Eight-week, Randomized, Open-label Trial." Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 25, no. 5, 2009, pp. 447-51.
Facio AC, Reis AS, Vidal KS, et al. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. J Ocul Pharmacol Ther. 2009;25(5):447-51.
Facio, A. C., Reis, A. S., Vidal, K. S., de Moraes, C. G., Suzuki, R., Hatanaka, M., & Susanna, R. (2009). A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, 25(5), 447-51. https://doi.org/10.1089/jop.2009.0018
Facio AC, et al. A Comparison of Bimatoprost 0.03% Versus the Fixed-combination of Latanoprost 0.005% and Timolol 0.5% in Adult Patients With Elevated Intraocular Pressure: an Eight-week, Randomized, Open-label Trial. J Ocul Pharmacol Ther. 2009;25(5):447-51. PubMed PMID: 19860553.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. AU - Facio,Antônio Carlos, AU - Reis,Alexandre Soares Castro, AU - Vidal,Kallene Summer Moreira, AU - de Moraes,Carlos Gustavo Vasconcelos, AU - Suzuki,Ricardo, AU - Hatanaka,Marcelo, AU - Susanna,Remo, PY - 2009/10/29/entrez PY - 2009/10/29/pubmed PY - 2010/1/15/medline SP - 447 EP - 51 JF - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JO - J Ocul Pharmacol Ther VL - 25 IS - 5 N2 - INTRODUCTION AND PURPOSE: Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension (OHT). The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure (IOP) after 8 weeks of treatment in patients with primary open angle glaucoma (POAG) or OHT. METHODS: In this randomized, open-label trial, 44 patients with POAG or OHT were allocated to receive either bimatoprost (1 drop QD) or latanoprost/timolol (1 drop QD). Primary outcome was the mean diurnal IOP measurement at the 8th week, calculated as the mean IOP measurements taken at 8:00 am, 10:00 am, and 12:00 pm Secondary outcomes included the baseline change in IOP measured 3 times a day, after the water-drinking test (performed after the last IOP measurement), and the assessment of side effects of each therapy. RESULTS: The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8. Also, the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns). During the water-drinking test, there was no significant difference in IOP increase (absolute and percentage) between groups; however, there was a significant decrease in mean heart rate in the latanoprost/timolol group. Finally, no significant changes in blood pressure and lung spirometry were observed in either groups. CONCLUSIONS: The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT. Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects. SN - 1557-7732 UR - https://www.unboundmedicine.com/medline/citation/19860553/A_comparison_of_bimatoprost_0_03_versus_the_fixed_combination_of_latanoprost_0_005_and_timolol_0_5_in_adult_patients_with_elevated_intraocular_pressure:_an_eight_week_randomized_open_label_trial_ L2 - https://www.liebertpub.com/doi/full/10.1089/jop.2009.0018?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -